Jasmin Bahlo

7.8k total citations
62 papers, 1.7k citations indexed

About

Jasmin Bahlo is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Jasmin Bahlo has authored 62 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Genetics, 46 papers in Pathology and Forensic Medicine and 29 papers in Immunology. Recurrent topics in Jasmin Bahlo's work include Chronic Lymphocytic Leukemia Research (60 papers), Lymphoma Diagnosis and Treatment (46 papers) and Immunodeficiency and Autoimmune Disorders (28 papers). Jasmin Bahlo is often cited by papers focused on Chronic Lymphocytic Leukemia Research (60 papers), Lymphoma Diagnosis and Treatment (46 papers) and Immunodeficiency and Autoimmune Disorders (28 papers). Jasmin Bahlo collaborates with scholars based in Germany, United States and Switzerland. Jasmin Bahlo's co-authors include Michael Hallek, Barbara Eichhorst, Kirsten Fischer, Stephan Stilgenbauer, Clemens‐Martin Wendtner, Valentin Goede, Hartmut Döhner, Paula Cramer, Sebastian Böttcher and Michael Kneba and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Jasmin Bahlo

59 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jasmin Bahlo Germany 21 1.3k 1.1k 553 327 246 62 1.7k
Javier Loscertales Spain 16 1.1k 0.8× 881 0.8× 467 0.8× 320 1.0× 222 0.9× 28 1.4k
Ahmed Hamdy United States 18 1.9k 1.5× 1.6k 1.4× 732 1.3× 668 2.0× 527 2.1× 60 2.5k
Nishitha Reddy United States 21 1.0k 0.8× 1.4k 1.2× 534 1.0× 511 1.6× 1.0k 4.1× 116 2.3k
Gregory A. Threatte United States 12 741 0.6× 625 0.5× 371 0.7× 208 0.6× 261 1.1× 22 1.4k
C Jacquillat France 15 1.5k 1.1× 1.2k 1.1× 770 1.4× 607 1.9× 590 2.4× 56 2.5k
Vincenzo Callea Italy 26 771 0.6× 630 0.5× 404 0.7× 1.3k 3.9× 797 3.2× 85 2.2k
Joshua Fein United States 16 405 0.3× 260 0.2× 220 0.4× 480 1.5× 354 1.4× 46 1.2k
Roberto Foà Italy 21 479 0.4× 461 0.4× 497 0.9× 455 1.4× 269 1.1× 60 1.3k
S. A. Roberts United Kingdom 14 88 0.1× 444 0.4× 430 0.8× 330 1.0× 52 0.2× 34 2.0k
Darrell White Canada 23 311 0.2× 456 0.4× 263 0.5× 1.3k 3.9× 1.0k 4.1× 134 1.9k

Countries citing papers authored by Jasmin Bahlo

Since Specialization
Citations

This map shows the geographic impact of Jasmin Bahlo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasmin Bahlo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasmin Bahlo more than expected).

Fields of papers citing papers by Jasmin Bahlo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jasmin Bahlo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasmin Bahlo. The network helps show where Jasmin Bahlo may publish in the future.

Co-authorship network of co-authors of Jasmin Bahlo

This figure shows the co-authorship network connecting the top 25 collaborators of Jasmin Bahlo. A scholar is included among the top collaborators of Jasmin Bahlo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jasmin Bahlo. Jasmin Bahlo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brieghel, Christian, Rudi Agius, Caspar da Cunha‐Bang, et al.. (2022). Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. European Journal Of Haematology. 108(5). 369–378. 12 indexed citations
2.
Agius, Rudi, Christian Brieghel, Michael Asger Andersen, et al.. (2020). Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nature Communications. 11(1). 363–363. 81 indexed citations
3.
Al‐Sawaf, Othman, Sandra Robrecht, Jasmin Bahlo, et al.. (2020). Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 35(1). 169–176. 62 indexed citations
4.
Al‐Sawaf, Othman, Alexandra Bazeos, Sandra Robrecht, et al.. (2019). Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology. 94(9). 1002–1006. 5 indexed citations
5.
Tresckow, Julia von, Barbara Eichhorst, Jasmin Bahlo, & Michael Hallek. (2019). The Treatment of Chronic Lymphatic Leukemia. Deutsches Ärzteblatt international. 116(4). 41–46. 10 indexed citations
6.
Herling, Carmen, Kevin R. Coombes, Axel Benner, et al.. (2019). Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. The Lancet Oncology. 20(11). 1576–1586. 15 indexed citations
7.
Sachanas, Sotirios, Gerassimos A. Pangalis, Anna‐Maria Fink, et al.. (2019). Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in “Real-Life” Outside of Clinical Trials. Anticancer Research. 39(5). 2591–2598. 3 indexed citations
8.
Agathangelidis, Andreas, Christof Schneider, Jasmin Bahlo, et al.. (2019). Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 105(11). 2598–2607. 41 indexed citations
9.
10.
Klymenko, Tetyana, Johannes Bloehdorn, Jasmin Bahlo, et al.. (2017). Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia. 32(2). 364–375. 22 indexed citations
11.
12.
Scheffold, Annika, Billy Michael Chelliah Jebaraj, Johannes Bloehdorn, et al.. (2017). High IGF1R Expression Is Associated with Worse Prognosis in CLL and Impacts Response to PI3K-δ Inhibitor Treatment. Blood. 130. 390–390.
13.
14.
Maurer, Christian, Petra Langerbeins, Jasmin Bahlo, et al.. (2016). Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL. Leukemia. 30(10). 2019–2025. 35 indexed citations
15.
Pflug, Natali, Sandra Kluth, Jörg Janne Vehreschild, et al.. (2016). Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. OncoImmunology. 5(6). e1150399–e1150399. 83 indexed citations
16.
Al‐Sawaf, Othman, Kirsten Fischer, Carmen Herling, et al.. (2016). Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. European Journal Of Haematology. 98(3). 254–262. 10 indexed citations
17.
Bahlo, Jasmin, Nadine Kutsch, Michael Bergmann, et al.. (2015). THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS. Haematologica. 100. 313–314. 6 indexed citations
18.
Goede, Valentin, Jasmin Bahlo, Barbara Eichhorst, et al.. (2015). Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leukemia & lymphoma. 57(4). 789–796. 73 indexed citations
19.
Kutsch, Nadine, Jasmin Bahlo, John C. Byrd, et al.. (2015). The international Prognostic Index for patients with CLL (CLL-IPI): An international meta-analysis.. Journal of Clinical Oncology. 33(15_suppl). 7002–7002. 14 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Javier Loscertales Breakdown of academic impact, for papers by Ahmed Hamdy Breakdown of academic impact, for papers by Nishitha Reddy Breakdown of academic impact, for papers by Gregory A. Threatte Breakdown of academic impact, for papers by C Jacquillat Breakdown of academic impact, for papers by Vincenzo Callea Breakdown of academic impact, for papers by Joshua Fein Breakdown of academic impact, for papers by Roberto Foà Breakdown of academic impact, for papers by S. A. Roberts Breakdown of academic impact, for papers by Darrell White
Rankless by CCL
2026